CORIXA CORP 4
4 · CORIXA CORP · Filed Jul 14, 2005
Insider Transaction Report
Form 4
CORIXA CORPCRXA
MOMSEN ROBERT R
Director
Transactions
- Disposition to Issuer
Common Stock
2005-07-12$4.40/sh−501,500$2,206,600→ 0 total(indirect: by InterWest Partners V, LP) - Disposition to Issuer
Common Stock
2005-07-12$4.40/sh−3,154$13,878→ 0 total(indirect: by InterWest Investors V, LP) - Disposition to Issuer
NQ Option (Right to Buy)
2005-07-12−20,060→ 0 totalExercise: $8.60From: 2003-07-30Exp: 2007-07-29→ Common Stock (20,060 underlying) - Disposition to Issuer
Common Stock
2005-07-12$4.40/sh−81,174$357,166→ 0 total - Disposition to Issuer
NQ Option (Right to Buy)
2005-07-12−15,000→ 0 totalExercise: $25.13From: 2005-07-12Exp: 2010-12-22→ Common Stock (15,000 underlying) - Disposition to Issuer
NQ Option (Right to Buy)
2005-07-12−5,000→ 0 totalExercise: $5.07From: 2005-07-12Exp: 2014-05-28→ Common Stock (5,000 underlying) - Disposition to Issuer
NQ Option (Right to Buy)
2005-07-12−7,500→ 0 totalExercise: $5.07From: 2005-07-12Exp: 2014-05-28→ Common Stock (7,500 underlying)
Footnotes (6)
- [F1]Disposed of pursuant to a merger agreement between the Issuer and GlaxoSmithKline PLC
- [F2]The shares are held by InterWest Partners V, LP ("IW5"). The general partner of IW5 is InterWest Management Partners V, LP ("IMP5"). The Reporting Person is a General Partner of IMP5 and disclaims beneficial ownership of the shares held by IW5 except to the extent of his pecuniary interest therein.
- [F3]The shares are held by InterWest Investors V ("II5"). The Reporting Person is a General Partner of II5 and disclaims beneficial ownership of the shares held by II5 except to the extent of his pecuniary interest therein.
- [F4]Option vests in 36 equal monthly installments and was fully vested prior to 7/12/05. The option was cancelled pursuant to the merger agreement between the Issuer and GlaxoSmithKline PLC. No cash consideration was received.
- [F5]Option vests in 12 equal monthly installments and was fully vested prior to 7/12/05. The option was cancelled pursuant to the merger agreement between the Issuer and GlaxoSmithKline PLC. No cash consideration was received.
- [F6]Option was fully vested prior to 7/12/05. The option was cancelled pursuant to the merger agreement between the Issuer and GlaxoSmithKline PLC. No cash consideration was received.